Skip to content
10-K

Annual Report

Lineage Cell Therapeutics, Inc. LCTX

0001193125-26-093992

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 5, 2026 249.09M sh
Shares Diluted FY 2025 · Dec 31, 2025 230.12M sh
Shares Diluted FY 2025 · Dec 31, 2024 200.19M sh
Capex FY 2025 · Dec 31, 2025 $522K
Capex FY 2025 · Dec 31, 2024 $565K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$18.92M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$23.09M
Cash And Equivalents FY 2025 · Dec 31, 2025 $40.79M
Cash And Equivalents FY 2025 · Dec 31, 2024 $45.79M
Stockholders Equity FY 2025 · Dec 31, 2025 $44.55M
Stockholders Equity FY 2025 · Dec 31, 2024 $78.38M
Current Liabilities FY 2025 · Dec 31, 2025 $11.37M
Current Liabilities FY 2025 · Dec 31, 2024 $13.98M
Total Liabilities FY 2025 · Dec 31, 2025 $69.24M
Total Liabilities FY 2025 · Dec 31, 2024 $36.21M
Current Assets FY 2025 · Dec 31, 2025 $59.16M
Current Assets FY 2025 · Dec 31, 2024 $51M
Total Assets FY 2025 · Dec 31, 2025 $112.58M
Total Assets FY 2025 · Dec 31, 2024 $113.22M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.28
Eps Diluted FY 2025 · Dec 31, 2024 −$0.09
Eps Basic FY 2025 · Dec 31, 2025 −$0.28
Eps Basic FY 2025 · Dec 31, 2024 −$0.09
Sga Expense FY 2025 · Dec 31, 2025 $18.46M
Sga Expense FY 2025 · Dec 31, 2024 $18.17M
Rd Expense FY 2025 · Dec 31, 2025 $17.73M
Rd Expense FY 2025 · Dec 31, 2024 $12.47M
Net Income FY 2025 · Dec 31, 2025 −$63.53M
Net Income FY 2025 · Dec 31, 2024 −$18.61M
Operating Income FY 2025 · Dec 31, 2025 −$36.62M
Operating Income FY 2025 · Dec 31, 2024 −$21.48M
Revenue FY 2025 · Dec 31, 2025 $14.56M
Revenue FY 2025 · Dec 31, 2024 $9.5M
Stock Issued FY 2025 · Jan 27, 2025 39.47M sh